Clinical trial / 2012
Acute administration of 300 mg EGCG increased EEG activity, enhanced self-rated calmness, and reduced self-rated stress compared to placebo.
In a double-blind, placebo-controlled crossover trial, participants completed baseline assessments of cognitive and cardiovascular functioning, mood, and resting state EEG before and 120 minutes following 300 mg EGCG or matched placebo. EGCG administration was associated with a significant overall increase in alpha, beta, and theta activity, which was also reflected in overall EEG activity and was more dominant in midline frontal and central regions (specifically the frontal gyrus and medial frontal gyrus). Compared to placebo, EGCG treatment also increased self-rated calmness and reduced self-rated stress.
- Study type
- Double-blind, placebo-controlled crossover study
- Who was studied
- Human participants (sample size not specified)
- What was measured
- Cognitive and cardiovascular functioning, mood, and resting state EEG activity
THE PAPER
Acute neurocognitive effects of epigallocatechin gallate (EGCG).
Scholey A, Downey LA, Ciorciari J, Pipingas A, Nolidin K, Finn M, Wines M, Catchlove S, Terrens A, Barlow E, Gordon L, Stough C. Appetite, 2012.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.